Medical artificial intelligence (AI) corporation Lunit announced on the 31st that it will develop an "AI-based personalized breast cancer whole-cycle integrated management platform" that can manage everything from breast cancer diagnosis and prediction to treatment planning, prognosis management, and follow-up screening.
The corporation has been selected for the project of the "2025 strategic technology international joint technology development project (global technology introduction type)" organized by the Korea Institute for Advancement of Technology (KIAT), under the Ministry of Trade, Industry and Energy, and will receive 3 billion won in research and development expenses, conducting the relevant research and development for three years until June 2028.
This project was established to enhance the technological competitiveness of domestic businesses and promote innovative activities, including entry into overseas markets.
The platform being developed this time is a next-generation breast cancer integrated management solution that enhances individual breast density, breast cancer risk assessment, and prognosis diagnosis, integrating AI technology. Lunit explained that it plans to enhance after the introduction of the technology owned by its subsidiary Volpara Health, including the "Volpara Scorecard" and "Volpara Density," and to expand Lunit AI reading technology from existing image analysis to risk prediction and follow-up management.
Once development is complete, the company's plan is to secure approval from the U.S. Food and Drug Administration (FDA) and obtain European CE certification, solidifying its leading position in the global breast cancer screening market, which is growing at an annual rate of more than 10%.
Seo Beom-seok, CEO of Lunit, noted, "The selection for this government project is significant in that Lunit's AI technological strength and global business strategy have once again been officially recognized by the government," adding, "We will develop next-generation solutions that provide practical help to both medical professionals and patients by combining the world-class breast cancer management technology secured through the acquisition of Volpara with Lunit's advanced AI capabilities."